


Alberta Pediatric High-Risk Program 2026-2027 RSV Prevention



Pathophysiology of RSV

RSV transmission methods

- Percentage of volunteers infected with RSV
- Absence of contact
  (volunteers seated at 2 m distance) 0%
- Indirect manual contact
  (contact with contaminated objects) 40%
- Close contact
  (children in volunteers' arms) 71%

Hall CB. J Pediatr 1980;141:10

Prevention of RSV

- Avoid large crowds (large family gatherings, childcare, air travel)



- Avoid sick contacts
- Avoid 2nd and 3rd hand smoke (Myhealthalberta.ca)
- Maternal Immunization:
  - Tdap one dose in every pregnancy, Annual Flu vaccine
  - RSV - 3rd trimester
- Ensure up to date vaccinations for close contacts for yearly flu and routine immunizations (Adult Tdap)

Most hospitalizations occur in the first 1-2 months of life

Alberta Health Services

RSV Immunization Passive/Active

INFANT PROTECTION (Passive Immunization)		OLDER ADULT PROTECTION (Active Immunization)
Monoclonal antibodies (mAbs): ◆ Nirsevimab (AstraZeneca & Sanofi) ◆ Palivizumab (AstraZeneca)	**Vaccines for people who are pregnant (to provide infant protection):** ◆ Pfizer vaccine	**Vaccines for older adults:** ◆ Pfizer vaccine

Alberta Health Services

Beyfortus stabilizing agents

Excipient List

Ingredient	50 mg/0.5 mL dose	100 mg/mL dose	Purpose in Product	Common Uses
Arginine Hydrocholoride	8 mg	17 mg	Stabilizer	Dietary supplements, protein shakes
L-histidine hydrochloride monohydrate	1.6 mg	3.3 mg	Acidity regulator	Antacids, food preservatives
Polysorbate 80	0.1 mg	0.2 mg	Emulsifier	Ice cream, cosmetics, salad dressings
Sucrose	21 mg	41 mg	Stabilizer	Table sugar, candies, soft drinks
Water for injection	USP	USP	Diluent (volume)	Purified water used in medical and pharmaceutical products


Does **NOT** contain gelatin (some individuals may be concerned about potential porcine or bovine origin).



Misinformation may lead to parent confusion and distrust of the child's healthcare

Alberta Health Services

RSV Prevention Program Web Page



Home > Information For > Health Professionals > Policies & Guidelines > Alberta Pediatric RSV Prevention Program

Alberta Pediatric Respiratory Syncytial Virus (RSV) Prevention Program

Policies & Guidelines, Info for Health Professionals

The Alberta Pediatric High Risk RSV Prevention Program is a collaborative initiative of the Northern (including Red Deer) and Southern Alberta High Risk RSV Prevention Programs that coordinates the identification and RSV immunoprophylaxis of eligible high-risk infants and children across Alberta.

ON THIS PAGE:

About RSV Immunoprophylaxis | Program Responsibilities | Eligibility Criteria & Referrals | RSV Season | Contact

About RSV Immunoprophylaxis

RSV immunoprophylaxis helps protect eligible infants and children against severe illness caused by respiratory syncytial virus (RSV).

Beyfortus® (nirsevimab)

Beyfortus® (nirsevimab) is a long-acting monoclonal antibody that provides passive immunity against RSV. It is the primary RSV immunoprophylaxis product currently used in Alberta for eligible infants during the RSV season.

Note: The Government of Alberta will be offering Beyfortus® (nirsevimab) free-of-charge to all babies born in the hospital during RSV season (November through April). For more information, see Respiratory Syncytial Virus Vaccine.

Product Information

- Beyfortus® Product Monograph

www.albertahealthservices.ca/info/rsvprogram.aspx

Alberta Criteria 26-27 season

ELIGIBILITY REQUIREMENTS

Provide a written communication, and site which criteria below the child has met.

This is the High-Risk Infant Program Criteria

1. Premature Infants
    1. **Premature infant:** less than or equal to **35 6/7 weeks gestational age** born after **April 30, 2026**
2. Infants on Intensive Care Units
    - **Any infant: less than one year of age** on date of admission to an intensive care unit (listed below) after **July 31, 2026**
        - Neonatal Intensive Care Units (NICU)
        - Pediatric Intensive Care Unit (PICU)
        - Pediatric Cardiac Intensive Care Unit (PCICU)

Alberta Criteria 26-27 season

3. Other High-Risk Categories
   In **term or pre-term infants: less than 2 years of age** as of **November 01, 2026,** including:
   - Persistent requirement for home oxygen
   - Congenital anomaly of airway e. trachea-esophageal fistula, Pierre Robin Sequence, laryngomalacia, tracheomalacia, vocal cord paralysis
   - Congenital anomaly of the lung e. congenital diaphragmatic hernia, congenital pulmonary airway malformation, interstitial lung disease.
   - Trisomy 21
   - Cardiac:
     - *Any infant with any cardiac defect,* ***less than one year of age*** *as of* ***November 01, 2026.***
     - *Severe hemodynamically significant congenital heart disease* ***between one- and two-years*** *of age as recommended by a cardiologist*
     - *Cystic Fibrosis, who are* ***less than one year of age*** *as of* ***November 01, 2026***

4. Other Category: No Age Restriction when Weight is Less than or Equal to 16 kg
   - Tracheostomies
   - Neuromuscular disorders
   - Significant immunodeficiency: severe combined immunodeficiency, stem cell transplant, or bone marrow transplant during the first-year post-transplant

5. **Any infant: less than one year of age as of November 01, 2026, residing on a First Nations Reserve.**

Alberta Health Services

Patients that reside on reserve that will be less than 1 yr of age on Nov 01, 2026

Patients in your area who will be **less than 1 year of age on November 1, 2026**, and who **did not receive Beyfortus® in hospital**, are eligible to receive Beyfortus.

Reminder:

All babies born in hospital between **November 1, 2026, and March 31, 2027,** will be offered Beyfortus before hospital discharge.

The Newborn sheet < medication administered. Will indicate whether Beyfortus® was administered during the hospital stay.

If you are unsure whether a dose has already been given this season, please contact Gail, Lisa, or Laura. They can verify administration in Connect Care or Netcare.

Nursing information

- **Beyfortus® is not a vaccine.** It provides ready-made antibodies that help protect babies against RSV.
- **More than 11 million babies worldwide have received Beyfortus®.**
- Beyfortus® is a form of **passive immunization**. It does not prevent every RSV infection, but it can **significantly reduce the risk of severe RSV illness and hospitalization.**
- Studies have shown a **70–80% reduction in RSV hospitalization** among infants who receive Beyfortus®.

Educate on everyday RSV prevention measures

Wash hands frequently

Avoid close contact with people who are sick

First Nation Clinic Packages are available from

RSV.Edmonton@ahs.ca/RSV.Calgary@ahs.ca

One Health RSV Prevention Program Resources

ab.cdc@sac-isc.gc.ca

- Pamphlet
- blank outpatient order
  - Individual client order required for all doses of Beyfortus
- blank dosing form



Beyfortus

- **An antibody, not a vaccine.** Antibodies act like a bodyguard for your baby's immune system, offering ready-made protection against RSV. Unlike vaccines, which train the body to respond over time, Beyfortus helps deliver a rapid defense against serious RSV lung infection—no training required.
- **Lowers risk of serious RSV disease**
- **Over 11† million babies** have been given Beyfortus to help protect them from serious RSV lung infection.

The most common side effects of Beyfortus include rash and pain, swelling, or hardness at the injection site.

Because your baby's lungs deserve protection against serious RSV lung infection.


RSV is unpredictable–while most cases are mild, it's hard to know which babies will get it or how severe it may become.

BEYFORTUS can give your baby a layer of protection from RSV, reducing the risk of hospitalization.

Please Talk to a

Women's and Child Health

Respiratory Syncytial Virus (RSV) Prevention



Nirsevimab (Beyfortus®) Outpatient Care Order

Pediatric/Neonatal Season 2026-2027

Authorized Prescriber please review order and sign at the bottom of document

Last Name:
First Name
Birthdate:
PHN/ULI
Criteria met as per program criteria for the 26-27 season:
Less than 1 year of age as of November 01, 2026, and will reside on reserve.
Allergies:

Restrictions for use of this order set: Only Patients approved by the Alberta Pediatric RSV Prevention Program having met specific criteria, or who have been approved by a Medical Director of the Northern or Southern Alberta RSV Prevention Programs. Administer RSV Prophylaxis only during RSV Season as determined by the Northern or Southern Alberta RSV Prevention Programs.

Nirsevimab (Beyfortus®) solution for injection

50 mg/0.5ml single-use, pre-filled syringe and 100 mg/1.0ml single-use, pre-filled syringe.

Single dose administration by intramuscular injection for eligible patients during an RSV Season.

First RSV Season < 8 months of age at time of administration

- Single fixed dose of 50 mg (0.5 mL) for infants weighing < 5 kg at time of administration
- Single fixed dose of 100 mg (1.0 mL) for infants weighing >=5 kg at time of administration

Second RSV Season >= 8 months of age at time of administration

- Single fixed dose of 200 mg (1.0 ml x 2 divided doses) administered in 2 different injection sites
- Consideration: If child weighs less than 10kg at time of administration in their second RSV season a single fixed dose of 100mg can be administered at clinical discretion who may require two injections, doses should be administered at different injection sites.

Assess patient for contraindications to inject Beyfortus®


- Implement Fit to Immunize Assessment prior to RSV prophylaxis
  https://www.albertahealthservices.ca/assets/info/hp/cdc/if-hp-cdc-ipsm-fit-to-immunize-tool.pdf

IF ADVERSE REACTION: follow clinic standards. Notify the most responsible MD/NP and the Northern Alberta RSV Prevention Program of adverse reaction

Discharge: Patient may be discharged after 15 minutes unless there are concerns.
No further dosing required unless contacted by the RSV Prevention Program

DATE:	Physician/ Nurse Practitioner	Signature

Fax Signed Document to 780-670-3223 Northern Alberta RSV Prevention Program



Alberta Health Services

LABEL

Alberta RSV Prevention Program 2026-2027

PLEASE FAX AFTER DOSE ADMINISTERED 780-670-3223

Notification of Beyfortus® Single fixed dose injection per season
First Nations RSV Prevention Clinic Name _____

First Name	Surname	ULI	Date of Birt dd-mmm-yy

Parent Name & Ph # _____

Date Given mm/dd/yy	Circle the dose administered	Lot #
Weight (Kg)	**Patient is under 8 months of age** 50 mg weighing less than 5 kg 100 mg weighing 5 kg to under 10 kg **Patient is greater than 8 months of age** 200 mg 2 x 100mg syringes (using 2 muscle sites)	# Syringes
Site (Lt, Rt)		

Consent documented ☐ **Outpatient order (PCO)** ☐

FAXED to Program ☐ **Beyfortus *SIGNED OFF* in CHIP** ☐

NOTES _____

Northern Alberta RSV Prevention Program
Telephone: (780)407-3978 fax: (780) 670-3223
www.albertahealthservices.ca

Alberta Health Services

Beyfortus

- **An antibody, not a vaccine.** Antibodies act like a bodyguard for your baby's immune system, offering ready-made protection against RSV. Unlike vaccines, which train the body to respond over time, Beyfortus helps deliver a rapid defense against serious RSV lung infection—no training required.
- **Lowers risk of serious RSV disease**
- **Over 11† million babies** have been given Beyfortus to help protect them from serious RSV lung infection.

The most common side effects of Beyfortus include rash and pain, swelling, or hardness at the injection site.

Because your baby's lungs deserve protection against serious RSV lung infection.

RSV is unpredictable–while most cases are mild, it's hard to know which babies will get it or how severe it may become.

BEYFORTUS can give your baby a layer of protection from RSV, reducing the risk of hospitalization.

Please Talk to a Healthcare Professional


Alberta Health Services | Covenant Health



Women's and Child Health

Respiratory Syncytial Virus (RSV) Prevention

Alberta Health Services | Covenant Health



WHAT IS RSV?

RSV is a virus that usually causes mild, cold-like symptoms, but can quickly and unpredictably become a serious lung infection in babies. These serious lung infections are a **leading cause** of hospitalization in babies. **RSV** is seasonal, usually lasts from fall to spring, peaking in the winter. While there are steps you can take to lower your babies chance of exposure, completely **eliminating the risk** is impossible.

- **Baby's lungs are still developing and can be especially vulnerable to RSV.**
- **For some babies RSV can escalate quickly, moving from mild cold-like symptoms to hospitalization in under a week.**
- **Serious RSV lung infections require constant monitoring, and can be an extremely stressful experience for new parents.**
- **Hospitalization can include needing breathing support and oxygen therapy, and often lasts a few days or longer.**



What is BEYFORTUS?

BEYFORTUS is a prescription medicine that is used to help prevent a serious lung disease caused by **Respiratory Syncytial Virus (RSV)**

BEYFORTUS is an **ANTIBODY** which is used to help prevent RSV disease for 5 months.

BEYFORTUS is a **Health Canada** approved medication and it was made for babies under the age of one born during or entering their first RSV season

Trifold pamphlet produced by AHS and Covenant
Will be used in inpatient units in Alberta and Outpatient clinics

Nirsevimab (Beyfortus®) Outpatient Care Order

Pediatric/Neonatal Season 2026-2027

Authorized Prescriber please review order and sign at the bottom of document

Last Name:
First Name
Birthdate:
PHN/ULI

Criteria met as per program criteria for the 26-27 season:
Less than 1 year of age as of November 01, 2026, and will reside on reserve.
Allergies:

Restrictions for use of this order set: Only Patients approved by the Alberta Pediatric RSV Prevention Program having met specific criteria, or who have been approved by a Medical Director of the Northern or Southern Alberta RSV Prevention Programs. Administer RSV Prophylaxis only during RSV Season as determined by the Northern or Southern Alberta RSV Prevention Programs.

Nirsevimab (Beyfortus®) solution for injection

50 mg/0.5ml single-use, pre-filled syringe and 100 mg/1.0ml single-use, pre-filled syringe.

Single dose administration by intramuscular injection for eligible patients during an RSV Season.

First RSV Season < 8 months of age at time of administration

- Single fixed dose of 50 mg (0.5 mL) for infants weighing < 5 kg at time of administration
- Single fixed dose of 100 mg (1.0 mL) for infants weighing >=5 kg at time of administration

---

Second RSV Season >= 8 months of age at time of administration

- Single fixed dose of 200 mg (1.0 ml x 2 divided doses) administered in 2 different injection sites
- Consideration: If child weighs less than 10kg at time of administration in their second RSV season a single fixed dose of 100mg can be administered at clinical discretion who may require two injections, doses should be administered at different injection sites.

Assess patient for contraindications to inject Beyfortus®

- Implement Fit to Immunize Assessment prior to RSV prophylaxis
  https://www.albertahealthservices.ca/assets/info/hp/cdc/if-hp-cdc-ipsm-fit-to-immunize-tool.pdf

IF ADVERSE REACTION: follow clinic standards. Notify the most responsible MD/NP and the Northern Alberta RSV Prevention Program of adverse reaction

Discharge: Patient may be discharged after 15 minutes unless there are concerns.
No further dosing required unless contacted by the RSV Prevention Program

DATE:	Physician/ Nurse Practitioner	Signature

Fax Signed Document to 780-670-3223 Northern Alberta RSV Prevention Program

Out-patient care order needs to be signed by a NP/Midwife/ Physician

If the RSV Prevention Program have been able to obtain an outpatient order, we will send it to the clinic the child will be attending

Alberta Health Services


Alberta Health Services

Dosing sheet

Circle the dose you gave

Record the date/weight/site/#of syringes used/ lot#

Fax/email the completed sheet to the Program so the information can be uploaded into connect care



Alberta Health Services

LABEL

Alberta RSV Prevention Program 2026-2027

PLEASE FAX AFTER DOSE ADMINISTERED 780-670-3223

Notification of Beyfortus® Single fixed dose injection per season
First Nations RSV Prevention Clinic Name _____

First Name	Surname	ULI	Date of Birth dd-mmm-yy

Parent Name & Ph # _____

Date Given *mm/dd/yy*	Circle the dose administered	Lot #
Weight (Kg)	**Patient is under 8 months of age** 50 mg weighing less than 5 kg 100 mg weighing 5 kg to under 10 kg **Patient is greater than 8 months of age** 200 mg 2 x 100mg syringes (using 2 muscle sites)	# Syringes
Site (Lt, Rt)		


Consent documented ☐ **Outpatient order (PCO)** ☐

FAXED to Program ☐ **Beyfortus *SIGNED OFF* in CHIP** ☐


NOTES _____


Northern Alberta RSV Prevention Program
Telephone: (780)407-3978 fax: (780) 670-3223
www.albertahealthservices.ca

Beyfortus: Documentation in CHIP




Beyfortus: Documentation in CHIP





Alberta Health Services

Alberta Health Services



Season Start date November 01, 2026

Are you ready?

- Informed verbal consent should be documented in the child's chart
- Do you have a signed order from and NP/Physician?
- Is it November 01, 2026-March 31, 2027?
- Do you have stock appropriate for the child's weight ?
- Do you have the Dosing sheet to fill in?

Infant dosing

Patient's initial season < 8 months of age single fixed dose at time of injection	
< 5 kg Body weight at time of injection	**50 mg preloaded syringe**

How to use Beyfortus®

Dosage and administration

A single administration based on infant's weight using a ready-to-use pre-filled syringe

An intramuscular injection, preferably in the anterolateral aspect of the thigh*



Dosing in infants with a body weight between 1.0 and 1.6 kg is based on extrapolation.

Infant/Pediatric dosing less than 8 months

Patient's initial season < 8 months of age single fixed dose at time of injection	
5kg or greater body weight at time of injection	**100 mg preloaded syringe**



Pediatric dosing greater than 8 months

Patient's 2nd RSV season >8 months of age single fixed dose during the active RSV season	
Greater than 5 kg Body weight at time of injection	**2 x 100 mg preloaded syringe given in a divided dose**

How to use Beyfortus®

Dosage and administration

A single administration based on infant's weight using a ready-to-use pre-filled syringe[1]

An intramuscular injection, preferably in the anterolateral aspect of the thigh[1*]



Dosing in infants with a body weight between 1.0 and 1.6 kg is based on extrapolation.


Preferred site for Beyfortus® Administration

Guidelines for solution amount, site, needle length and gauge

	Vastus Lateralis	Deltoid	Ventrogluteal	Dorsogluteal	Length (inches)	Gauge
Infant	0.5 ml	Not recommended	Not recommended until 7 months, then 0.5 ml	Not recommended	5/8 – 1	22-25
Toddler	0.5-1 ml	0.5 ml	1 ml	Not recommended	5/8 – 1	22-25
Preschooler	1 ml	0.5 ml	1.5 ml	Not recommended	5/8 – 1	22-25
School Age	1.5-2 ml	0.5-1 ml	1.5-2 ml	1.5 – 2 ml	5/8 – 1.5	22-25


Reference: Canadian Essentials of Pediatric Nursing (2013) pg 349





Alberta Health Services

How to administer Beyfortus®



Step 1

Holding the **Luer lock** in one hand (avoid holding the **plunger rod** or **syringe body**), unscrew the **syringe cap** by twisting it counter clockwise with the other hand.

Step 2

Attach a **Luer lock needle** to the pre-filled syringe by gently twisting the needle clockwise onto the pre-filled syringe until slight resistance is felt.

Reference: 1. Beyfortus® Product Monograph, June 14, 2024.

How to administer Beyfortus®

Step 3

Hold the **syringe body** with one hand and carefully pull the needle cover straight off with the other hand. Do not hold the **plunger rod** while removing the needle cover or the **rubber stopper** may move.

Do not touch the needle or let it touch any surface. Do not recap the needle or detach it from the syringe.

Step 4

Administer the entire contents of the Beyfortus® pre-filled syringe as an intramuscular injection, preferably in the anterolateral aspect of the thigh.

The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.

Step 5

Dispose of the used syringe immediately, together with the needle, in a sharps disposal container or in accordance with local requirements.

If two injections are required, repeat steps 1-5 in a different injection site.

Reference: 1. Beyfortus® Product Monograph, June 14, 2024.

Common Q+A's for Beyfortus®

What was the safety profile of Beyfortus® in clinical trials?

Beyfortus® was generally well tolerated in clinical trials:

- The most frequent adverse reaction was a rash (0.7% in Beyfortus® and 0.3% in placebo, occurring within 14 days post dose), as well as pyrexia (0.5% vs. 0.6% in placebo) and injection site reactions (0.3% vs. 0% in placebo) within 7 days post dose.
- The safety profile for Beyfortus® was generally comparable to placebo in term and preterm infants (GA ≥29 weeks) (data pooled from Study 3 and MELODY).

Confidential – not for distribution – this information is classified as Beyfortus® competitively sensitive information and is provided to you on a need-to-know basis and for business legitimate reasons. This information is provided to you personally and may only be used for the benefit of Beyfortus®

Beyfortus® Ordering

- Beyfortus® ordering is through the RSV Prevention Program.

- Each First Nations clinic is unique and may receive Beyfortus® stock directly or through your local public health.

If you have any questions, please email or call

RSV.Edmonton@ahs.ca 780-407-3978/RSV.Calgary@ahs.ca 403-955-3195

Receiving Beyfortus ®

- **Routinely check inventory**, rotate shorter dated stock to the front, and ensure shortest dated product is used first.

How to store Beyfortus®[1]

Storage



- Store in a refrigerator (2–8°C)
- Do not freeze
- Do not shake or expose to heat
- Keep the pre-filled syringe in the outer carton in order to protect from light



Beyfortus® may be kept at room temperature (20–25°C) when protected from light for a maximum of 8 hours. After this time, the syringe must be discarded.

Pack options available

Available as a ready-to-use
pre-filled syringe[1]



Beyfortus® is available in a pack containing 1 single-use, sterile, pre-filled syringe without needle. Each single-use, pre-filled syringe contains a solution of 50 mg nirsevimab in 0.5 mL (100 mg/mL) or 100 mg nirsevimab in 1 mL (100 mg/mL).

COLD CHAIN

Must be reported to the RSV Prevention Program by email.
RSV.Edmonton@ahs.ca
RSV.Calgary@ahs.ca

Beyfortus ® is not managed by public health

Cold Chain Violation Protocol Summary- If a cold chain breach occurs for **Beyfortus®/Nirsevimab**:

1. **Do not contact your hospital pharmacy.**
2. Instead, email: RSV.Edmonton@ahs.ca
3. **Include the following details in your email:**
   a. Number of Beyfortus syringes involved
   b. Expiry date and lot #'s of the affected vials
   c. Maximum or minimum temperature reached, type of thermometer used
   d. Duration out of cold chain
4. **Immediate Action:**
   a. Return Beyfortus® to the fridge (2°C to 8°C) **ASAP**
   b. Clearly **mark it as a cold chain violation**
5. **Next Steps:**
   a. The RSV Prevention Program will report the incident to **Sanofi Medical**
   b. **Sanofi Medical** will determine the medication's viability—not the hospital pharmacy

Date Mm dd yy	# of Syringes	Lot #	Expiry date on Syringes	Type of thermometer used	Max/Min temp reached	Time out of cold chain
	50mg x ____					
	100mg x____					
	50mg x ____					
	100mg x____					
	50mg x ____					
	100mg x____					

Alberta Health Services



Thank you

ISC CDC: ab.cdc@sac-isc.gc.ca
Gail Porter-Lai RSV.Edmonton@ahs.ca
Lisa Loczy RSV.Calgary@ahs.ca

Alberta Health Services